{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T05:06:29Z","timestamp":1735707989064,"version":"3.32.0"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":2278,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:p>Objective: To assess adverse effects and immune responses with a three\u2010dose series of <jats:italic>Haemophilus influenzae<\/jats:italic> type b meningococcal protein conjugate (PedvaxHIB or Hib.OMP) vaccine, including any immunological response alterations from concurrent administration with routine vaccines for infants.<\/jats:p><jats:p>Design: Randomized, controlled trial with treatment group crossover for dose 3.<\/jats:p><jats:p>Setting: Two public health units near Vancouver.<\/jats:p><jats:p>Participants: One hundred and ten healthy infants eight to 14 weeks old were enrolled; 105 completed the study (95%).<\/jats:p><jats:p>Interventions: All participants received two doses of diphtheria\u2010pertussis\u2010tetanus (<jats:sc>dpt<\/jats:sc>) vaccine (at two and four months of age) and one dose of measles\u2010mumps\u2010rubella (<jats:sc>mmr<\/jats:sc>) vaccine at 12 months. In each instance, Hib.OMP was given either concurrently in another limb or after a delay of two weeks (after <jats:sc>dpt<\/jats:sc>) or four weeks (after <jats:sc>mmr<\/jats:sc>).<\/jats:p><jats:p>Main Outcome Measures: Adverse effects, particularly fever and local erythema, were monitored by parents for 72 h after each dose of Hib.OMP vaccine. Five blood samples were taken at prescribed intervals to assess responses to each dose of Hib.OMP and to selected other vaccine antigens.<\/jats:p><jats:p>Main Results: Follow\u2010up was obtained after all 322 doses of Hib.OMP. Local adverse effects were infrequent and mild: 13% had redness, 17% tenderness. Systemic effects in those given Hib.OMP alone included fever in 8%, irritability in 29%. Anti\u2010polyribose\u2010ribitol phosphate (<jats:sc>prp<\/jats:sc>) responses to Hib.OMP were not impaired by coadministration with <jats:sc>dpt<\/jats:sc> or <jats:sc>mmr<\/jats:sc> vaccines, nor were tetanus or diphtheria antitoxin levels or rubella or measles response rates affected. After two doses of Hib.OMP, 92% were seropositive and 64% had greater than 1.0 \u03bcg\/mL of anti\u2010<jats:sc>prp<\/jats:sc>. After three doses, 100% were seropositive and 82% exceeded 1.0 \u03bcg\/mL.<\/jats:p><jats:p>Conclusion: Hib.OMP vaccine was well tolerated, immunogenic and compatible with vaccines routinely given to infants in Canada.<\/jats:p>","DOI":"10.1155\/1994\/479313","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T07:57:54Z","timestamp":1458028674000},"page":"75-81","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of <i>Haemophilus influenzae<\/i> Type B Conjugate Vaccine (Meningococcal Protein Conjugate) in Canadian Infants"],"prefix":"10.1155","volume":"5","author":[{"given":"David W","family":"Scheifele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordean L","family":"Bjornson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G","family":"Meekison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Guasparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie A","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1993,10,6]]},"container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/1994\/479313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/1994\/479313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T05:04:25Z","timestamp":1735621465000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/1994\/479313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,10,6]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1155\/1994\/479313"],"URL":"https:\/\/doi.org\/10.1155\/1994\/479313","archive":["Portico"],"relation":{},"ISSN":["1712-9532","1918-1493"],"issn-type":[{"type":"print","value":"1712-9532"},{"type":"electronic","value":"1918-1493"}],"subject":[],"published":{"date-parts":[[1993,10,6]]}}}